Eli Lilly gains rights to Adocia's experimental ultra-rapid insulin under potential $570-million deal

Eli Lilly entered a global licensing deal with Adocia potentially worth up to $570 million to develop the ultra-rapid insulin BioChaperone Lispro for treatment in people with type 1 and type 2 diabetes. The therapy, which uses Adocia's BioChaperone technology, is currently in Phase Ib studies.

"An ultra-rapid acting insulin, if approved by regulators, could provide a new important treatment option for people with type 1 and type 2 diabetes," remarked Enrique Conterno, president of Eli Lilly's diabetes unit. The executive added "an ultra-rapid acting insulin would be a natural fit in our growing portfolio."

Under the agreement, Eli Lilly will assume responsibility for future development, manufacturing and commercialisation of BioChaperone Lispro. The company will make an upfront payment of $50 million to Adocia, with the latter eligible to receive future payments of up to $280 million if the drug reaches certain development and regulatory milestones, and sales milestones up to $240 million, as well as tiered sales royalties. The drugmakers noted that a concentrated formulation of BioChaperone Lispro is also part of the deal.

Eli Lilly currently markets insulin lispro under the brand Humalog.

For related analysis, see ViewPoints: Adocia revives diabetes collaboration with Eli Lilly.

To read more Top Story articles, click here.